Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.41 |
| ▸ | CASP2 | P42575 | 1/20 | 0.40 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25332483 | 1.00 | KDM4E (0.50) | KDM4EMAPK1HIF1AEPHX1ADRA1A | |
| SCHEMBL691823 | 0.97 | KDM4E (0.46) | KDM4EMAPK1HIF1AEPHX1ADRA1A | |
| SCHEMBL4965925 | 0.92 | — | — | |
| SCHEMBL18874871 | 0.89 | CA3 (0.45) | KDM4EMAPK1HIF1AEPHX1ADRA1A | |
| SCHEMBL10656502 | 0.87 | PAOX (0.44) | KDM4EMAPK1HIF1AEPHX1ADRA1A | |
| SCHEMBL2720594 | 0.87 | PAOX (0.44) | KDM4EMAPK1HIF1AEPHX1ADRA1A | |
| SCHEMBL15871737 | 0.87 | KDM4E (0.55) | KDM4EMAPK1HIF1AEPHX1ADRA1A | |
| SCHEMBL20836564 | 0.87 | KDM4E (0.55) | KDM4EMAPK1HIF1AEPHX1ADRA1A | |
| SCHEMBL5569558 | 0.87 | KDM4E (0.55) | KDM4EMAPK1HIF1AEPHX1ADRA1A | |
| SCHEMBL453216 | 0.87 | KDM4E (0.55) | KDM4EMAPK1HIF1AEPHX1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097229-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED DERMATOLOGICAL CONDITIONS | BACAINN BIOTHERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2023-08-17 | — | — | US | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| EP-4172149-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | Bacainn Biotherapeutics, Ltd. (KY) | 2023-05-03 | — | — | EP | disclosed |
| US-20220227808-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC | 2022-07-21 | — | — | US | disclosed |
| US-11254705-B2 | Cyclic peptide analogs and conjugates thereof | SIRENAS LLC (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2022005881-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | BACAINN BIOTHERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20190211060-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | SIRENAS LLC (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | NLRP3, PYCARD, NLRP1 | KDM4E 4511/4885MAPK1 2257/4885HIF1A 579/4885 |
| US-20190211060-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | VIP, NGLY1, GRPR | KDM4E 4553/4885MAPK1 3945/4885HIF1A 1662/4885 |
| US-11254705-B2 | Cyclic peptide analogs and conjugates thereof | VIP, NGLY1, GRPR | KDM4E 4553/4885MAPK1 3945/4885HIF1A 1662/4885 |
| US-20220227808-A1 | CYCLIC PEPTIDE ANALOGS AND CONJUGATES THEREOF | VIP, NGLY1, GRPR | KDM4E 4553/4885MAPK1 3945/4885HIF1A 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.